Both the mutations in MEN1 and DAXX/ATRX suggest that targeting these epigenetic mechanisms with small molecule compounds may be a viable approach to developing new therapeutics for pancreatic NETs. Here, MEN1 is linked to pancreatic neuroendocrine tumor.